Theory and practice

Eleventh-hour disappointments at FDA advisory committee meetings sometimes seem to be more the rule than the exception.

MedImmune's experience last week is hardly the first time a company has crashed and burned in a panel meeting. What surprises us each time is that a company can get so far down the road before it hears adamant objections from the agency that must approve its product...